Amber Ophthalmics (SAN DIEGO, CA)
Apr 22, 2023
Amber Ophthalmics to present Phase 2 study results for NEXAGON in subjects with PCED at ARVO Annual Meeting
Join the Amber Team at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in New Orleans, LA. Learn more about the conference here: https://www.arvo.org/annual-meeting/
Amber will present additional results from EXPEDE (NEX-PED-005) with 35 completed subjects:
Title: A Phase 2, randomized, prospective, double-masked, vehicle-controlled study to assess the safety and efficacy of topical NEXAGON in subjects with persistent corneal epithelial defects (PCED) resulting from sever ocular chemical and/or thermal injuries
Posterboard #: C0271
Session date: April 25, 2023, 11:45AM-1:30PM (CDT)
NEXAGON (lufepirsen ophthalmic gel) is a first-in-class, patent protected, naturally occurring, unmodified antisense oligonucleotide that restores ocular surface homeostasis by downregulating pathogenically elevated connexin 43 protein transcription. This prohibits connexin 43 hemichannel formation quelling unregulated inflammation associated with PCED. NEXAGON has been granted orphan drug designation by the FDA for the indication of PCED.
PCED is a rare and progressive disease impacting an estimated 100,000 patients in the United States per year that arises from the failure of corneal re-epithelialization within 10-14 days of a corneal insult, even with the use of standard supportive treatment. Despite treatment, and regardless of underlying etiology, if progression is not halted PCED can result in corneal scarring, vascularization, and/or severe vision loss. There are currently no FDA approved therapies for the treatment of PCED.